2012

Cynvenio Biosystems Co-Sponsors And Will Exhibit At The World Ctc Forum On November 12-15 In Boston, Mass.

October 9, 2012 - Cynvenio Biosystems, Inc. announced today that it will be co- sponsoring the 3rd annual World CTC USA meeting, at the Hyatt Regency in Boston, Massachusetts on November 12-15, 2012. The World CTC conference brings together the pre-eminent academic and industry researchers focusing on the biotechnology of Circulating Tumor Cells and their impact on drug development and patient treatment.

National Cancer Institute Awards $1.4M Phase II SBIR Grant to Cynvenio Biosystems, Inc.

July 31, 2012 - Cynvenio Biosystems, Inc. announced that the National Cancer Institute (NCI) awarded the company a $1.4 million Phase II Small Business Innovative Research (SBIR) contract to partially fund the development and commercialization of a novel microfluidic technology for scaled-up production of aptamers for use as specific binding agents.

Cynvenio Biosystems Co-Founder & Chairman Honored by the Scholarship Foundation of Santa Barbara

Fred Gluck will receive the 2012 Pioneer Award for outstanding contributions in innovation, service and leadership.

Westlake Village, CA — May 14, 2012—Cynvenio Biosystems, Inc., a developer of rare cell isolation systems for biomedical research in circulating tumor cells, personalized medicine and the molecular diagnostics of cancer, announced today that Fred Gluck, its co-Founder and Chairman of the Board, will be the recipient of the 2012 South Coast Pioneer Award.

The Scholarship Foundation of Santa Barbara will honor Fred Gluck and four other outstanding companies and individuals at the South Coast Business & Technology Awards dinner on June 14, 2012 at Fess Parker’s Doubletree Resort in Santa Barbara, California. Now in its 18th year, the South Coast Business & Technology Awards was designed to honor individuals and organizations who have demonstrated an extraordinary commitment to helping the South Coast of Santa Barbara County remain economically vital.

Fred Gluck is a Brooklyn boy who has enjoyed a variety of careers including butcher boy, check clearing (nights), magazine sales (Catholic Home Messenger), ballistic missile defense, top management consulting, health care delivery, and engineering and construction. Since moving to Santa Barbara in 1998 with his wife, Linda, Fred has been active in various community service roles (Cottage Hospital System, UCSB Foundation, Kavli Institute of Theoretical Physics) and as an entrepreneur in biotech drug development and medical equipment.

He was a Founder of CytomX, LLC in 2006 and led the company as Chairman and CEO during the initial two years of technology development and market definition. In 2008, the company spun off Cynvenio Biosystems, Inc. and Fred continued as Chairman of both companies. Cynvenio recently announced and is now commercializing its successful, first-in-class development of a LiquidBiopsy™ system for early cancer detection and post-operative monitoring. CytomX Therapeutics is developing Probodies™ – a new class of powerful antibody drugs with substantially reduced toxic side effects. The first Probodies™ are expected to be in the clinic in late 2013. Fred is also an investor and Board member of TrueVision Systems, Inc., the market leader in flat panel 3D HDTV systems for computer-aided microsurgery.

Fred was with McKinsey & Co. from 1967 to 1995 and led the Firm as its elected Managing Director (CEO) from 1988 to 1994. During the 6 years he led the Firm, McKinsey doubled in size and greatly expanded its international presence, particularly in Asia, Eastern Europe and Latin America. Fred also led the Firm’s technology and strategic management practices for many years and wrote and spoke extensively on those subjects during that period. Fred’s pioneering contributions to the development of the discipline of corporate strategy are featured in Walter Kiechel’s recently published book The Lords of Strategy.

Fred retired from McKinsey and joined The Bechtel Group in February 1995 serving as Vice-Chairman and Director. Fred retired from Bechtel in July 1998 and rejoined McKinsey and Company as a consultant to the Firm.

Before joining McKinsey, Fred spent 10 years with Bell Telephone Laboratories as a rocket scientist and was the program manager for the Spartan anti-ICBM missile. In 1967, Bell Labs nominated Fred for the Eta Kappa Nu Award as the country’s Outstanding Young Electrical Engineer.

Fred earned a B.S.E.E from Manhattan College in 1957 and an M.S.E.E. from New York University in 1959. In addition, he did graduate studies in Operations Research at Columbia University.

Fred recently retired after 15 years of service as a Director of AMGEN (Thousand Oaks, CA) [NASDAQ] and was the presiding director of HCA (Nashville, TN) [NYSE] prior to its LBO in 2007. He was Vice-Chairman of New York Hospital prior to its merger with Columbia Presbyterian and now enjoys Emeritus status after 36 years of service.

About Cynvenio Biosystems, Inc.

Cynvenio Biosystems, Inc. is a privately held company focused on the development of the LiquidBiopsy™ platform, a high performance rare cell isolation technology for biomedical research and novel cancer diagnostics. As a precursor to next generation sequencing and the mutational profiling of cancer cells retrieved from whole blood, LiquidBiopsy™ is a key enabling technology to realize the promise of personalized medicine – including the early detection of disease, real time monitoring of patients, and the selection of individual therapeutic solutions. Cynvenio is based in Westlake Village, California. Find more information at www.cynvenio.com

Cynvenio to Present at the 103rd American Association for Cancer Research (AACR) Annual Meeting on its Proprietary CTC Isolation Flow Cell and the Workflow for the Analysis of DNA Mutations in CTC

March 25, 2012—Cynvenio Biosystems, Inc. announced that it will be presenting a poster at the 103rd Annual Meeting of the American Association for Cancer Research taking place at the McCormick Center in Chicago. The presentation will describe Cynvenio’s proprietary Circulating Tumor Cell (CTC) isolation flow cell and the workflow for the analysis of DNA mutations in circulating tumor cells (CTC).

Cynvenio Biosystems and USC Norris Cancer Center to Present Clinical Data on Mutational Analysis of Liquidbiopsy® Tumor Samples at the 2013 AACR Annual Meeting

March 25, 2012—Cynvenio announced that it will be presenting a poster at the 103rd Annual Meeting of the American Association for Cancer Research taking place at the McCormick Center in Chicago, next week. The presentation will describe Cynvenio’s proprietary Circulating Tumor Cell (CTC) isolation flow cell and the workflow for the analysis of DNA mutations in circulating tumor cells (CTC).

National Cancer Institute Awards Two Lung Cancer Circulating Tumor Cell (CTC) Development Contracts to Cynvenio Biosystems, Inc.

February 7, 2012—Cynvenio Biosystems, Inc. announced that the National Cancer Institute (NCI) awarded two Small Business Innovative Research (SBIR) contracts to develop novel lung cancer tests based on the isolation of mutation-bearing Circulating Tumor Cells (CTCs) from whole blood. The company also announced that it has received an additional $1.2 million from existing shareholders as part of a fully committed $2.0 million financing authorized by its board of directors.